CLINUVEL (ASX:CUV) has announced final results from its Phase 2 pilot study evaluating SCENESSE (afamelanotide) as a monotherapy in patients with the depigmentation disorder vitiligo. …
Pilot study confirms adjunct NB-UVB needed to activate repigmentation in vitiligo
June 18, 2025 Australian Biotech
Latest Video
New Stories
-
ARCS evolves into LifeSciences Australia as part of wider strategic change
June 11, 2026 - - Latest News -
Sigma confirms interest in the acquisition of UK pharmacy chain Boots
June 10, 2026 - - Latest News -
Island secures US partnership to advance Galidesivir dose study for Marburg
June 10, 2026 - - Australian Biotech -
Cartherics secures Japanese patent to bolster cell therapy push
June 10, 2026 - - Australian Biotech -
GSK to buy Nuvalent in a major move to acquire rights to late stage lung cancer candidates
June 10, 2026 - - Latest News -
Australian company secures US fast track for CAR-T in blood cancers
June 10, 2026 - - Latest News -
Industry campaign highlights MFN risk to US jobs and the broader economy
June 10, 2026 - - Latest News